Delayed Graft Function (DGF) after Kidney Transplantation

Medical Need:

Organ injury and damage from Oxidative Stress and Ischemia Reperfusion are unavoidable consequences of kidney transplantations and are associated with a high rate of organ failure and patient mortality. They happen during ischemic time which can last up to 24 hours and the reperfusion after reimplantation of the organ. During the transplantation process, the organ goes through ‘warm’ and ‘cold’ ischemic times, as shown in the chart below.





The short-term clinical symptom showing the organ damage is defined as “Delayed Graft Function (DGF)”. Patients with Delayed Graft Function need dialysis during the first week after kidney transplantation to stabilize their kidney function. Delayed Graft Function is correlated with reduced organ survival and increased mortality of the organ recipient.

The PrC-210 Effect during Transplantation:

PrC-210 has been shown in animal
experiments to reduce apoptosis in
transplanted kidneys to the level of
normal nontransplanted kidneys during
both cold ischemic time and reperfusion
time.

The complete scavenging and capture
of Free Radicals by PrC-210 and
inhibition of apoptosis led to significant reduction of
tubular cell damage during 30 hours Cold
Ischemia and total cell protection during
Reperfusion.

Based upon the animal data, PrC-210 will be
administered during the entire transplantation
process in order to protect the transplant organ
from the donor to the recipient.

If organ damage is reduced, the

♦   organ survival time will be increased, and
♦   the recipient mortality could be reduced.
♦   This will lead to a reduction of second and
     third organ  transplantations and to a reduced
     number of patients on the waiting list and
     thereby shortens the time to organ transplantation.
     The average time on the waiting list per kidney is
     between 2 and 8 Years.

* Devin Incerti; The lifetime health burden of DGF in Kidney Transplant Recipients in
the US; sagepub.com/journalsPermissions.nav DOI: 10.1177/2381468318781811

There is currently still no approved drug for the prevention of DGF.